세계의 자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장(유형별, 지역별) : 부문별 예측(2025-2035년)

Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market By Type (Cervical Cancer Screening, Cervical Cancer Diagnostics, Pre-cancerous Lesion Treatment), By Region, And Segment Forecasts, 2025 - 2035

US $ 5,950 ￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

세계의 자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장 성장과 동향 :

Grand View Research, Inc의 최신 보고서에 따르면 세계의 자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장 규모는 2035년까지 156억 7,504만 달러에 달할 것으로 예측되고, 2025년부터 2035년까지 CAGR 5.90%를 보일 것으로 예측됩니다.

시장 성장의 원동력은 기술의 진보, 의식의 향상, 예방의료에 대한 강한 관심입니다. 이환율과 사망률을 줄이기 위해서는 조기 발견, 혁신적인 치료법, 공정한 의료 접근에 대한 지속적인 투자가 필수적입니다.

첨단 검진 및 치료 기술의 급속한 도입은 시장 확대의 주요 요인이 되고 있습니다. 예를 들어, 2024년 7월, Aspirus Woodruff Clinic에서는 Loop Electrosurgical Excision Procedure(LEEP) 장비의 도입으로 레이크랜드 여성들이 최첨단 자궁 경부 치료를 받을 수 있게 되었습니다. 이 기술은 자궁 경부 이형성의 치료에 있어서 큰 전진이며, 이사회 인정의 부인과 의사인 Joelle Wennlund는 자궁경부암 예방에 있어서 중요한 역할을 강조하고 있습니다. 마찬가지로, 2021년 1월, Pregna International Ltd.은 CryoPop 동결요법 장비를 출시하여 여성 건강 관리의 리더로서의 입지를 강화했습니다. Jhpiego와의 제휴에 의해 개발된 CryoPop은 자궁경부암 박멸을 위한 WHO의 세계 전략에 따라 세계에서 자궁경부 전암 병변 치료에 대한 접근을 향상시킵니다.

자궁경부암 검진 및 치료 업계에서 가장 큰 성장 기회 중 하나는 비용 효율적이고 이용하기 쉬운 검진 기술의 개발과 도입입니다. 고소득국가의 자궁경부암 이환율 저하에 있어서, 팹스메어는 역사적으로 중요한 역할을 해 왔지만, 전문적인 인재와 검사 시설의 인프라에 의존하고 있기 때문에 자원에 제약이 있는 환경에서는 그 실현성에 한계가 있습니다. 이러한 과제를 해결하기 위해 세계보건기구(WHO)는 보다 이용하기 쉬운 검진방법을 포함하도록 가이드라인을 갱신하고, 충분한 서비스를 받지 못한 지역에서의 검진률 향상과 조기 발견 촉진을 목표로 하고 있습니다. WHO의 자궁경부암 박멸을 위한 세계 전략은 2030년까지 35세와 45세 여성의 70%를 고성능 검사로 검진하는 것을 목표로 하고 있습니다. 이 이니셔티브는 세계 검진 프로그램의 확대에 대한 WHO의 헌신을 부각시켜 시장의 성장 가능성을 높이고 있습니다.

팹스메어 등의 기존 자궁경부암 검진법은 오랫동안 최적표준이었습니다.

자궁경부암 진단에 있어서의 인공지능(AI)의 통합은 게임 체인저이며, 검진의 효율에 혁명을 가져왔습니다. AI가 내장된 진단 시스템은 디지털화된 세포 진단 슬라이드를 자동으로 평가하고 추가적인 임상 검사를 위해 잠재적인 비정상적인 플래그를 지정할 수 있습니다.

AI의 영향은 진단에 그치지 않고, 치료 계획에도 이르게 됩니다. 엄청난 혜택을 받으면서 낮은 침습으로 매우 효과적인 개입과 회복 시간을 단축할 수 있습니다.

자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장 : 분석 개요

• 유형별로는 자궁경부암 검진 분야가 2024년에 48.29%의 최대 수익 점유율로 시장을 선도해 예측기간 중 가장 빠른 CAGR로 성장할 것으로 예측됩니다.
• 자궁경부암 진단 시장은 생검 기기와 질경의 진보에 더해 이러한 기술에 대한 채용과 수요가 증가하고 있기 때문에 예측기간 중에 대폭적인 CAGR이 예상됩니다.
• 북미가 2024년에 41.17%의 최대 매출 점유율로 시장을 독점했습니다. 이러한 이니셔티브는 팹스메어(세포학)와 최근에는 인유두종 바이러스(HPV) 검사에 크게 의존하고 있습니다. cobas HPV 및 BD Onclarity HPV 분석과 같은 HPV 자기 채취 검사의 최근 FDA 승인은 불쾌감, 문화적 과민성 또는 과거 외상으로 인해 기존의 골반 검사를 피할 수있는 여성에게 유망한 선택을 제시합니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장 : 변동 요인, 경향, 범위

• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회의 분석
• 자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장 : 정성 데이터 분석

• 자궁경부암 검진 가이드 라인
• 자궁경부암 검진의 활용
• WHO 및 기타 정책위원회의 입장
• 자궁경부암 검진의 장벽

제5장 자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장 : 동향 분석

• 신흥기술과 혁신 동향
• 상환의 정세
• 자궁경부암 발생률과 유병률
• 총대상인구
• HPV 백신접종을 받은 집단의 동향의 평가

제6장 자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장 : 유형별 추정 및 동향 분석

• 시장 점유율 : 유형별(2024년·2035년)
• 부문별 대시보드
• 자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장 : 유형별 전망
• 자궁경부암 검진
  • 팝 스메어 채취 기구
  • HPV 검사 플랫폼
  • 사이트 브러쉬
  • 자기 채취 키트
  • 기타
• 자궁경부암 진단
  • 질경
  • 자궁 경부 생검 기기
  • AI 영상 탑재 코르포스코프(디지털)
  • 기타
• 전암 병변 치료
  • LEEP(루프 전기 수술 절제술) 장치
  • 동결요법
  • 열 절제
  • 기타

제7장 자궁경부암 검진, 진단 및 전암 이형성 병변 치료 시장 : 지역별 추정 및 동향 분석(제품별, 유형별, 최종 용도별)

• 시장 점유율 분석 : 지역별(2024년·2035년)
• 시장 대시보드 : 지역별
• 세계 시장 현황 : 지역별
• 시장 규모 예측과 동향 분석(2018-2035년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 진출기업별
• 기업/경쟁의 분류
• 주요 기업의 시장 점유율/위치 분석(2024년)
• 기업 프로파일
  • F. Hoffmann-La Roche
  • BD
  • Abbott
  • QIAGEN
  • Hologic, Inc.
  • CooperSurgical Inc.
  • MedGyn Products, Inc
  • WISAP Medical Technology GmbH
  • Liger Medical
  • Utah Medical Products, Inc.

JHS

영문 목차

영문목차

Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Growth & Trends:

The global cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market size is anticipated to reach USD 15,675.04 million by 2035 and is projected to grow at a CAGR of 5.90% from 2025 to 2035, according to a new report by Grand View Research, Inc. The market growth is driven by technological advancements, increased awareness, and a strong focus on preventive care. Despite persistent challenges such as disparities in healthcare access and the ongoing burden of cervical cancer, collaborative efforts among federal agencies, healthcare providers, and community organizations are fostering improved outcomes. Continued investment in early detection, innovative treatment options, and equitable healthcare access will be critical in reducing cervical cancer incidence and mortality. As the market expands, stakeholders must prioritize cost-effective solutions and innovative screening technologies to ensure comprehensive coverage across diverse populations.

The rapid adoption of advanced screening and treatment technologies has been a key driver of market expansion. For instance, in July 2024, women in Lakeland gained access to state-of-the-art cervical care at Aspirus Woodruff Clinic with the introduction of a Loop Electrosurgical Excision Procedure (LEEP) machine. This technology marks a major step forward in the treatment of cervical dysplasia, with Dr. Joelle Wennlund, a Board-certified Gynecologist, emphasizing its critical role in cervical cancer prevention. Similarly, in January 2021, Pregna International Ltd. reinforced its position as a leader in women's healthcare by launching the CryoPop cryotherapy device. Developed in partnership with Jhpiego, CryoPop enhances accessibility to cervical pre-cancerous lesion treatment worldwide, aligning with WHO's global strategy for cervical cancer elimination.

One of the most significant growth opportunities in the cervical cancer screening and treatment industry is the development and implementation of cost-effective, accessible screening technologies. While Pap smears have historically played a crucial role in reducing cervical cancer rates in high-income countries, their reliance on specialized personnel and laboratory infrastructure limits their feasibility in resource-constrained settings. To address these challenges, the World Health Organization (WHO) has updated its guidelines to include more accessible screening methods, aiming to increase coverage and promote early detection in underserved regions. WHO's Global Strategy for the Elimination of Cervical Cancer seeks to screen 70% of women with a high-performance test at ages 35 and 45 by 2030. This initiative highlights the organization's commitment to expanding global screening programs, reinforcing the market's growth potential.

Traditional cervical cancer screening methods, such as Pap smears, have long been the gold standard. However, they are increasingly being supplemented by technological advancements such as liquid-based cytology and high-risk HPV DNA testing. These approaches improve sample quality, enhance diagnostic accuracy, and reduce turnaround time, making early detection more effective.

The integration of artificial intelligence (AI) in cervical cancer diagnostics has been a game changer, revolutionizing screening efficiency. AI-driven tools can now analyze cytological images with high precision, identifying abnormal cells that could indicate pre-cancerous or cancerous lesions. For example, AI-powered diagnostic systems can automatically evaluate digitized cytology slides, flagging potential abnormalities for further clinical review. This not only reduces human error but also expedites diagnostic processes, leading to faster medical interventions.

AI's impact extends beyond diagnostics to treatment planning. With machine learning and predictive analytics, healthcare providers can better assess lesion progression and offer personalized treatment approaches. Technologies such as LEEP and cryotherapy benefit significantly from AI precision, ensuring minimally invasive, highly effective interventions with shorter recovery times. In regions where healthcare infrastructure is limited, AI-driven solutions help scale screening programs efficiently, making high-quality diagnostics and treatment more accessible.

Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market Report Highlights:

• Based on type, the cervical cancer screening segment led the market with the largest revenue share of 48.29% in 2024 and is expected to grow at the fastest CAGR during the forecast period. Cervical cancer screening is essential for early detection and prevention, utilizing a variety of devices and technologies to enhance accuracy, accessibility, and patient outcomes. Traditional Pap smear collection tools remain a cornerstone of screening, particularly in areas lacking advanced diagnostic infrastructure
• The cervical cancer diagnostics market is anticipated to witness at a substantial CAGR during the forecast period, driven by advancements in biopsy devices and colposcopes, alongside increasing adoption and demand for these technologies. In December 2024, the Federal Capital Territory Administration introduced a colposcopy machine designed to enhance early detection and treatment of cervical cancer among women. This groundbreaking initiative is expected to revolutionize healthcare delivery in the region.
• North America dominated the market with the largest revenue share of 41.17% in 2024. North America has made remarkable progress in reducing cervical cancer incidence and mortality over the past several decades, primarily through extensive cervical cancer screening programs. These initiatives rely heavily on Pap smears (cytology) and, increasingly, human papillomavirus (HPV) testing. However, despite high overall screening rates in many regions, disparities persist in screening participation and follow-up care, particularly among underserved populations. To address these gaps, healthcare systems across North America are adopting innovative solutions. Recent FDA approvals for HPV self-collection tests, such as the cobas HPV and BD Onclarity HPV assays, present a promising alternative for women who may avoid traditional pelvic exams due to discomfort, cultural sensitivities, or past trauma

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Variables, Trends & Scope

• 3.1. Market Dynamics
  • 3.1.1. Market driver analysis
  • 3.1.2. Market restraint analysis
  • 3.1.3. Market opportunities analysis
• 3.2. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Analysis Tools
  • 3.2.1. Industry Analysis - Porter's
    • 3.2.1.1. Supplier power
    • 3.2.1.2. Buyer power
    • 3.2.1.3. Substitution threat
    • 3.2.1.4. Threat of new entrant
    • 3.2.1.5. Competitive rivalry
  • 3.2.2. PESTEL Analysis
    • 3.2.2.1. Political landscape
    • 3.2.2.2. Economic landscape
    • 3.2.2.3. Social landscape
    • 3.2.2.4. Technological landscape
    • 3.2.2.5. Environmental landscape
    • 3.2.2.6. Legal landscape

Chapter 4. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market, Qualitative Data Analysis

• 4.1. Screening Guidelines for Cervical Cancer
• 4.2. Utilization of Cervical Cancer Screening
• 4.3. WHO and Other Policy Board Positions
• 4.4. Barriers to Cervical Cancer Screening

Chapter 5. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market, Market Developments Analysis

• 5.1. Emerging Technology and Innovation Trends
• 5.2. Reimbursement Landscape
• 5.3. Incidence and Prevalence of Cervical Cancer
• 5.4. Total Eligible Population
• 5.5. Assessing Trends in HPV-Vaccinated Populations

Chapter 6. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market: Type Estimates & Trend Analysis

• 6.1. Type Market Share, 2024 & 2035
• 6.2. Segment Dashboard
• 6.3. Global Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market by Type Outlook
• 6.4. Cervical Cancer Screening
  • 6.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.4.2. Pap Smear Collection Devices
    • 6.4.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.4.3. HPV Testing Platforms
    • 6.4.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.4.4. Cytobrush
    • 6.4.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.4.5. Self-collection kits
    • 6.4.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Market estimates and forecast, 2018 to 2035 (USD Million)
• 6.5. Cervical Cancer Diagnostics
  • 6.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.5.2. Colposcopes
    • 6.5.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.5.3. Cervical Biopsy Devices
    • 6.5.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.5.4. Colposcopes with AI Imaging (Digital)
    • 6.5.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.5.5. Others
    • 6.5.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
• 6.6. Pre-cancerous Lesion Treatment
  • 6.6.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.6.1.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.6.2. LEEP (loop electrosurgical excision procedure) Machine
    • 6.6.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.6.3. Cryotherapy
    • 6.6.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.6.4. Thermal Ablation
    • 6.6.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.6.5. Others
    • 6.6.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)

Chapter 7. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market: Regional Estimates & Trend Analysis, By Product, By Type, By End Use

• 7.1. Regional Market Share Analysis, 2024 & 2035
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2035:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts, 2018 to 2035 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts, 2018 to 2035 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts, 2018 to 2035 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts, 2018 to 2035 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2035 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Key company market share/position analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. F. Hoffmann-La Roche
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Technology Type benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. BD
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Technology Type benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Abbott
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Technology Type benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. QIAGEN
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Technology Type benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Hologic, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Technology Type benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. CooperSurgical Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Technology Type benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. MedGyn Products, Inc
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Technology Type benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. WISAP Medical Technology GmbH
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Technology Type benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Liger Medical
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Technology Type benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Utah Medical Products, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Technology Type benchmarking
    • 8.4.10.4. Strategic initiatives

관련자료